Transcripts
Molina Healthcare, Inc.'s management answers for the business every quarter. These are the exchanges that explain it best — verbatim, from the call transcripts preserved in Sources. Each link opens the full transcript at that page in a new tab.
Q1 FY2026 Earnings Call — Q1 FY2026
The clearest post-shock read on how Molina’s Medicaid economics work — acuity, cost trend, and why management still refuses to raise guidance early. · Open the full transcript →
Why membership can fall without an acuity hit: the low/no-utilizer purge is done and leavers now depart at portfolio-average cost.
Mark Keim (CFO): Yes, absolutely, Andrew. The states Joe mentioned — California, Illinois, New York and Texas — are why we are expecting somewhat higher attrition this year. In California, the undocumented immigration status members are disproportionately driving that trend. Our prior guidance assumed membership attrition of 2% for the year; in the updated guidance it is now 6%, so membership volume will be lower. In our prepared remarks we noted that revenue would be offset by the marketplace. However, to Joe’s point about a potential acuity impact from higher Medicaid attrition, we are not seeing that. Most of the low- and no-utilizers left over the past 1.5 to 2 years since redetermination began after the pandemic, and today we have a smaller percentage of low and no users in our Medicaid population than we have ever recorded. Our stayers-versus-leavers analysis shows that those leaving Medicaid are leaving at rates very close to portfolio averages, which further suggests any pent-up acuity shift is largely behind us. So yes, Medicaid membership is lower, but we do not see an acuity impact.
p. 4 · Read in context →
Guidance philosophy: why a strong quarter still won’t move the full-year number until two quarters season.
Joseph Zubretsky (President and CEO); Kevin Fischbeck (Bank of America): Our prudent move to not increase guidance at the first quarter, even though the indicators are all positive for all 3 businesses are for vastly different reasons. In Medicaid, the volatility of the network cost inflection we experienced in late 2025, we had a very good trend result. In fact, the annualized trend result in the first quarter would indicate we might even come in less than 5% for the year, but we're not yet calling that. In Marketplace, we want to wait to see the June Wakely data before truing up our estimate for the full year. And we had a very, very good start in our new integrated products, our FIDE and HIDE in Medicare, but it's 1 quarter. It's a brand-new product, existing members, but a brand-new product. We want to see that develop for another quarter. We use the term time tested because I think it is prudent to see 6 months of results before updating our guidance, particularly coming off a highly volatile medical cost inflection environment in 2025, bearing in mind in Medicaid with a 92% result in the first quarter a 92.9% indication in our guidance for the full year, we can actually produce loss ratios north of 93% and still hit our guidance for the rest of the year. So cautious perhaps, but in this environment, we think it's entirely prudent to do so.
p. 5 · Read in context →
How the Medicare book is being rebuilt around duals — D-SNP, the converted HIDE/FIDE members, and the MAPD product being exited.
Joseph Zubretsky (President and CEO); Scott Fidel (Goldman Sachs): You're right to point out that the Medicare story is a little more complicated than most because it's a combination of our D-SNP product, which has been in force for many years; our MMP members who have now converted to HIDE and FIDE; and our MAPD product, which we are going to eliminate for 2027. We cited a drag on this year's earnings due to the MAPD product — I think we said it produced about a $1 earnings per share drag that won't repeat next year — and it is tracking to plan. D-SNPs have always produced a modest profit and continue to. The surprise, if there was one, is that we took a very cautious approach to converting 80,000 members and over $2 billion of revenue to HIDE and FIDE, which are highly competitive new products under a new rating regime. They performed much better out of the gate than we had anticipated, but that's just one quarter, so we'll be cautious about updating guidance for the full year on that product. In 2027 and beyond we'll only be talking about duals: D-SNP and HIDE and FIDE combined as a dual segment, which will be a lot easier to follow. Those are the three pieces, and they will have different dynamics for different reasons.
p. 8 · Read in context →
Capital allocation: buying distressed plans near book value can beat a new contract win because the capital is all regulatory, not goodwill.
Joseph Zubretsky (President and CEO); John Stansel (JPMorgan): Our M&A pipeline is full of actionable opportunities. We'll remain disciplined and focus on properties that fit our core strategy. Mark and I debate this often: historically we paid around 22 to 23 percent of revenue, but book value now seems the best benchmark. If you're only paying for regulatory capital, an M&A deal can be as good as, if not better than, a new contract win.
p. 9 · Read in context →
Unit economics: the cost base is 20% higher than three years ago, and Molina runs 300-400 bps better than the market as states catch up.
Joseph Zubretsky (President and CEO); Lance Wilkes (Bernstein): Generally speaking, we're seeing states step up to the reality that a cost inflection has occurred and they are catching up to it. What do they need to catch up to? If you look at the trends we've experienced over the past three years, 4.5, 6.5 and 7.5, the cost baseline is 20% higher than it was three years ago. That's what they need to catch up to. Now we believe we're operating 300 to 400 basis points better than the average market. So as they catch up, we should be moving into much more positive territory than we already are. Bearing in mind, our guidance in Medicaid is for a 1.5% pretax margin this year, eliminating the impact of Florida Kids.
p. 11 · Read in context →
Q3 FY2025 Earnings Call — Q3 FY2025
The second guidance cut of the year and the sharpest map of the recovery — how underfunded rates catch up, why the exchange book is being shrunk, and how Molina buys revenue at book value. · Open the full transcript →
The framing that anchors the thesis: a rate-trend dislocation is inclement weather, not climate change — temporary, not permanent.
Joseph Zubretsky (CEO): At our last Investor Day, we characterized this environment as inclement weather rather than climate change, metaphorically meaning temporary rather than permanent. We continue to believe this to be true.
p. 3 · Read in context →
The deliberate exchange retreat: 30% average 2026 rate hikes, a 20% smaller footprint, top-2 pricing dropping from 50% of markets to ~10%.
Mark Keim (CFO): Our 2026 rate increases averaged 30%, ranging from 15% to 45%, and we have exited difficult geographies. I will note that for the next year, we have reduced our county footprint by 20%, and our #1 and #2 price position is going from 50% of our footprint in 2025 to an estimated 10% of our footprint in 2026.
p. 4 · Read in context →
The recovery math: the market needs 300-500 bps of rate to break even, but Molina runs 200-300 bps ahead, so it needs only a fraction.
Joseph Zubretsky (CEO); Joshua Raskin (Nephron Research): The market in Medicaid needs 300 to 500 basis points to break even, just to break even. We've consistently operated 200 to 300 basis points better than the competitors in all of our markets. We only need a fraction of what the market needs in order to get back to target margins.
p. 7 · Read in context →
The M&A model in one answer: $11B of revenue acquired over ~8 deals at 22% of revenue — mostly hard regulatory capital, near book value.
Joseph Zubretsky (CEO); John Stansel (JPMorgan): On the M&A pipeline, if you look at our history of purchasing, what, $11 billion of revenue over 7 or 8 deals and only acting capital equal to 22% of purchase revenue, half of which is regulatory capital, hard capital we barely paid any goodwill value for the acquisitions. In this period of cyclically low margins, we're going to be very disciplined about prices paid for revenue streams. If you can buy a revenue stream from a struggling local health plan at or about book value, it's just as good as winning a new contract, no goodwill capital.
p. 10 · Read in context →
How Medicaid rates actually get set: the look-back start date matters less than the trend factor layered on top of it.
Mark Keim (CFO); Michael Ha (Baird): And Joe, that's a big point that isn't always well understood. If the look-back period is 6 months or 12 months ago, sure, that makes a difference from one perspective, but that's not the rate you get. The rate you get is that look back starting point plus a fair trend on top of it. Now actuaries can argue over what that fair trend is on top of it. But if that fair trend comes out at an appropriate place, the specific data, the look-back period is less relevant.
p. 13 · Read in context →
Q2 FY2025 Earnings Call — Q2 FY2025
The call where the thesis first broke — a $5.50 guidance cut — and where management laid bare the rate/trend/corridor machinery and its “small, silver and stable” exchange discipline. · Open the full transcript →
How the dislocation built quarter by quarter as rising trend outran each rate update and drained the risk corridors.
Joseph Michael Zubretsky (President and CEO): Starting in the third quarter of 2024, while an increasing trend emerged from the end of the redetermination process, rates and Molina's risk corridor positions at the time were sufficient to offset that increasing trend. By the fourth quarter of 2024, the increasing medical cost trend moved beyond the 2024 midyear rate updates, and corridors have largely become depleted. Moving into the first quarter of 2025, the January 1 rate cycle captured much of the continued trend pressure. And now in the second quarter of 2025, we experienced yet another increase in trend, which moved beyond the rate updates received in the first quarter, and risk corridor protection at this point is very limited and isolated.
p. 2 · Read in context →
Why Marketplace is deliberately capped at 10% of the portfolio: inherent volatility and a constantly shifting risk pool.
Joseph Michael Zubretsky (President and CEO): Our small, silver and stable approach to this line of business, where we target mid-single-digit margins even at the expense of growth, was deliberate and well considered. This line of business has significant inherent volatility and a constantly shifting risk pool. We have limited this segment to just 10% of our portfolio, and we always approach it cautiously.
p. 3 · Read in context →
Why risk adjustment stopped protecting the exchange book: the whole national risk pool is 8% more acute year-over-year.
Joseph Michael Zubretsky (President and CEO); Joshua Raskin (Nephron Research): The acuity of the entire marketplace risk pool is higher by 8% year-over-year, which means on a relative basis, risk adjustment is not going to keep up with the elevated trend.
p. 7 · Read in context →
The distance to target margin, spelled out: 190 bps over the range, needing ~200 bps of rate on top of trend to get back.
Joseph Michael Zubretsky (President and CEO); Kevin Fischbeck (Bank of America): Currently, we are operating at a 91% medical cost ratio, which is 190 basis points above the upper limit of our range. To reach our target margin, we need an additional 200 basis points on top of the trend. Based on external evaluations, we believe that the wider market will require even more than this. If we can secure those extra 200 basis points along with an appropriate trend, we should be able to return to our target margin.
p. 11 · Read in context →
What embedded earnings is: $8.65 built from $2.25 of acquisitions, $5.40 of contract wins, and $1 of reversing implementation costs.
Mark Keim (CFO); Jason Cassorla (Guggenheim): So the $8.65 is comprised of about $2.25 from acquisitions and about $5.40 from new contract wins. You add in $1 of the implementation cost that's in our P&L this year that just automatically reverse next year. Those are the components that get you to $8.65 million. Now the good news, and Joe pointed this out, is the dollar has no execution risk. It just happens.
p. 15 · Read in context →
Q4 & Full Year 2024 Earnings Call — Q4 FY2024
The pre-storm annual call that lays out the whole growth algorithm — 19% premium growth, the $46B/$52B revenue targets, embedded earnings, and how rates, trend and corridors fit together. · Open the full transcript →
The growth algorithm: wins and acquisitions put Molina on a path to $46B (2026) and $52B (2027); embedded earnings ~30% of run-rate EPS.
Joe Zubretsky (CEO): we are well on our way to meeting our target of $46 billion premium revenue in 2026, and at least $52 billion in 2027. With our current footprint contributing its average annual growth, and now fully considering all of our recent growth successes, the path to achieve these growth milestones is very clear. And most importantly, all of this recent activity has allowed us to increase our embedded earnings to $7.75 for 2026 and beyond, after harvesting $1.50 of embedded earnings in our 2025 guidance. Having embedded earnings of at least 20 to 25% of run rate EPS is an attractive benchmark to support future EPS growth. Now at approximately 30%, we are very well positioned to meet our long-term targets.
p. 2 · Read in context →
The exchange playbook before the pool turned: two years of double-digit margins reinvested into pricing to grow.
Joe Zubretsky (CEO): Finally, in Marketplace, we are projecting to grow premium at 60% in total, half of which is organic. Two consecutive years of exceeding target margins have allowed us to reinvest several hundred basis points of excess margin into pricing in order to grow.
p. 2 · Read in context →
How risk corridors really work — an imperfect hedge that only helps where trend pressure and remaining corridor protection line up.
Mark Keim (CFO); Andrew Mok (Barclays): We're in 21 states. And the benefit of the corridor is not evenly distributed across 21 states. So what really matters is where does the trend pressure show up versus where is corridor protection remaining. That could either help you significantly or it can leave you no benefit, which is more or less what happened in the fourth quarter.
p. 6 · Read in context →
Decomposing medical cost trend: 2024’s 6.5% was half redetermination acuity, half core utilization — and the acuity half does not recur.
Joe Zubretsky (CEO); Sarah James (Cantor Fitzgerald): In 2024, in Medicaid, our full cost trend was 6.5%, half of which was the acuity shift to redetermination and half of which is what we call core utilization, high utilization of the continuing population. Comparing that to the 4.5% trend in 2025, the acuity shift doesn't recur.
p. 8 · Read in context →
The regulatory thesis: any real Medicaid cut forces a politically untenable choice, so changes to managed Medicaid should be marginal.
Joe Zubretsky (CEO); A.J. Rice (UBS): The issue is what are you going to reduce in terms of where the money goes? […] Neither side of the aisle wants to see more uninsured. It's below ten percent of eligibles for the first time in decades. Reduction in benefits. Reduction in enrollment, reduction in payments to providers, or none of the above. And I either have to, as a state, decrease my education budget or raise taxes. None of those solutions is politically tenable. That's why we conclude that any changes to manage Medicaid as we know it today would be marginal.
p. 11 · Read in context →
More calls
Q1 FY2025 Earnings Call — Q1 FY2025 · 12 pages · The last call before the mid-2025 reset — management still reaffirming $24.50 and the embedded-earnings growth story just before trend broke it. · Open →
Q3 FY2024 Earnings Call — Q3 FY2024 · 14 pages · Where the cost inflection first surfaced in the continuing Medicaid population, beyond the redetermination acuity shift. · Open →
Q2 FY2024 Earnings Call — Q2 FY2024 · 13 pages · A mid-redetermination read on how acuity shift, rates and corridors were still holding Medicaid MCR near target. · Open →
Q1 FY2024 Earnings Call — Q1 FY2024 · 12 pages · The early-redetermination baseline: the operating model running to plan before the trend environment turned. · Open →
Q4 & Full Year 2023 Earnings Call — Q4 FY2023 · 13 pages · Where the $46B/$52B multi-year growth targets and the embedded-earnings framework were first laid out in detail. · Open →
Q3 FY2023 Earnings Call — Q3 FY2023 · 12 pages · Peak-redetermination membership dynamics and how Molina reaffirmed its long-term compound growth target through the unwind. · Open →
Q2 FY2023 Earnings Call — Q2 FY2023 · 15 pages · The height of the Medicaid redetermination unwind — the clearest early framing of how acuity and rate corridors protect the book. · Open →